Choosing Itacitinib for GVHD Prophylaxis: Insights From Popat
Uday R. Popat, MD, discusses the rationale behind evaluating itacitinib over other JAK inhibitors for graft-vs-host disease prophylaxis in a phase 2 study.
Related Articles
Key Takeaways From the RATIONALE-305 Trial
The panelists discuss how tislelizumab’s clinical performance in the RATIONALE-305 trial was evaluated through multiple end points, including overall survival, progression-free survival, and adverse event…
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
Key PointsA longer interval between prior CAR-T and mosunetuzumab is associated with a higher response rate to mosunetuzumab.After prior CAR-T, mosunetuzum
Call for Abstracts – WCLC 2025
Submit your abstract to IASLC 2025 World Conference on Lung Cancer (WCLC 2025) in Barcelona, Spain, from September 6–9, 2025.
Celebrating Women in Oncology Through Their Impactful Research and Insights
For International Women’s Day, CancerNetwork highlights impactful oncology research on topics from rising health care costs to innovative treatments.
JNCCN 360 – Non–Small Cell Lung Cancer – CSF Circulating Tumor Cell Assay for Diagnosing Leptomeningeal Disease in NSCLC
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…
Larotrectinib Demonstrates Efficacy, Safety for Patients With TRK Fusion-Positive Gastrointestinal Cancers
According to results from a retrospective analysis, larotrectinib demonstrated promising efficacy and safety among patients with TRK fusion-positive gastrointestinal cancers, including colorectal cancer.
Salvage ASCT Shows No Significant Survival Vs Lenalidomide Combo in Myeloma
The absence of a PFS and OS benefit in the transplant arm was consistent across key subgroups in the phase 3 GMMG ReLApsE trial.
“Errol was brave and fearless – we feel his loss enormously” – Rider’s story
Rider McDowell’s son Errol was diagnosed with medulloblastoma, a fast-growing malignant brain tumour, when he was 12. Despite six years of intensive treatment, Errol passed…
FDA Approves Mirdametinib for NF1-Associated Plexiform Neurofibromas
The FDA has approved mirdametinib for patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas.
